Warning: The NCBI web site requires JavaScript to function. more...
Generate a file for use with external citation management software.
Research Center of Innovative Cancer Therapy, Kurume University School of Medicine, 67 Asahimachi, Kurume, Fukuoka 830-0011, Japan.
Despite advances in radiation and chemotherapy along with surgical resectioning, the prognosis of patients with malignant glioma is poor. Therefore, the development of a new treatment modality is extremely important. There are increasing reports demonstrating that systemic immunotherapy using peptide is capable of inducing an antiglioma response. This review highlights peptide-based immunotherapy for glioma patients. Peptide-based immunotherapy strategies appear promising as an approach to successfully induce an antitumor immune response and increase survival in patients with glioma. Peptide-based therapy of glioma seems to be safe and without major side effects. Biotherapy for malignant glioma with peptide will open a novel reality now.
Your browsing activity is empty.
Activity recording is turned off.
Turn recording back on